Page last updated: 2024-08-26

paxilline and Bone Diseases, Metabolic

paxilline has been researched along with Bone Diseases, Metabolic in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Feyen, J; Glatt, M; Green, J; Jeschke, M; Missbach, M; Müller, K; Susa, M1

Other Studies

1 other study(ies) available for paxilline and Bone Diseases, Metabolic

ArticleYear
A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo.
    Bone, 1999, Volume: 24, Issue:5

    Topics: 3T3 Cells; Animals; Bone Diseases, Metabolic; Bone Resorption; Cell Adhesion Molecules; Cell Survival; CSK Tyrosine-Protein Kinase; Cytoskeletal Proteins; Disease Models, Animal; Enzyme Inhibitors; Female; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Male; Mice; Oncogene Protein pp60(v-src); Osteoblasts; Ovariectomy; Paxillin; Phosphoproteins; Phosphorylation; Pregnancy; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; src-Family Kinases

1999